# Agios Pharmaceuticals Inc. (AGIO) fundamentals

Data as of 2026-09-08. NASDAQ, United States. Sector: Healthcare / Biotechnology. Price $33.10, market value $2.0 billion.

## Valuation
- **P/E (trailing): n/a** (negative earnings). Agios Pharmaceuticals Inc. reported negative earnings over the last twelve months, so the P/E is not meaningful; use price-to-sales, EV/EBITDA and free-cash-flow yield instead.
- **Price / sales: 20.1×**. Each dollar of revenue is priced at 20.1×, a level that requires very high margins or very fast growth to justify.
- **Price / book: 1.9×**. The shares trade at 1.9× book value; book value is a meaningful part of the valuation.
- **Free-cash-flow yield: -18.5%** (5-yr avg -21.9%). Free cash flow is negative: the business is consuming cash, which is normal for heavy investment phases but a warning otherwise.

## Profitability
- **Operating margin: -466.8%**. Operating margin is negative: the business loses money before interest and tax.
- **Net margin: -764.0%**. The company reported a net loss over the last twelve months.
- **Return on equity: -34.6%**. Return on equity is negative because earnings are negative.
- **Return on assets: -31.7%**. Each dollar of assets produces -31.7% of profit.

## Growth
- **Revenue growth (1 yr): 48.0%** (3-yr 56.0%/yr). Revenue grew 48.0% over the last year.
- **EPS growth (1 yr): -161.2%**. Earnings per share fell 161.2%, slower than revenue, so margins compressed.

## Financial health
- **Current ratio: 11.46** (quick 11.46). Current assets cover the next year's liabilities 11.46 times.
- **Altman Z-score: 12.31**. A Z-score of 12.31 places the company in the safe zone for bankruptcy risk.
- **Piotroski F-score: 2/9**. 2 of 9 checks pass: weak or deteriorating financials.

## Dividends
- **Dividend: none**. Agios Pharmaceuticals Inc. does not currently pay a dividend.

## Analyst view
- **Analyst consensus: buy** (8 analysts). 8 analysts cover Agios Pharmaceuticals Inc.; the consensus is buy, with an average price target of $45.75 (+38% from the current price). Analyst opinion is shown for context; it is not part of the Fundamental Score.

## Price and momentum
- **Total return (1 yr): -8.4%** (YTD 21.6%, 3-mo 17.0%). The shares are down 8.4% over twelve months including dividends.
- **From 52-week high: -28.0%** (48.8% above the low). Trading 28% below its 52-week high.
- **200-day average: above**. The price sits above its 200-day moving average, the usual definition of an uptrend.
- **RSI (14-day): 45**. An RSI of 45 is neutral.
- **Beta (1 yr): 0.55** (volatility 76%). Beta of 0.55 against the S&P 500: the shares move much less than the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=AGIO · Page: https://foliofundamentals.com/stocks/agio

Not investment advice.